PyongSu Joint Venture Company

From Wikipedia:

PyongSu Joint Venture Company, Limited is a pharmaceutical company jointly founded in 2002 by Pyongyang Pharmaceutical Company in North Korea and a company headquartered in Hong Kong which is a market leader in pharmaceuticals distribution and contract manufacturing in Asia. The corporate headquarters of PyongSu are in the Songyo district in Pyongyang. PyongSu started trial production in 2004 and, as of 2005, engaged in manufacturing mainly painkillers and antibiotics. At the end of 2006 the foreign-invested stake was sold to another investor. Felix Abt, the 3rd managing director (or president) managed to avoid the closure of the company by turning the heavily loss-making operation into a profit-making one. PyongSu became the first North Korean pharmaceutical factory to reach GMP (a universally recognized quality standard in the pharmaceutical industry as defined by the WHO), repeatedly inspected and confirmed by the WHO. It also became the first ever North Korean company to participate in tender competitions and to win contracts against foreign competitors from China, India, Germany and elsewhere. With an increasing cash-flow generated by itself, the company has even become able to buy and profitably operate pharmacies and other sales outlets in the country. Towards the end of 2008 managing director Felix Abt explained that the company now enjoys 1) a portfolio of products made by itself including an anti-helmintic and an anti-hypertensive drug that meets the patients’ needs well 2) a good reputation as a quality and service-minded company in the DPR Korea and the recognition as the “model company” of the domestic pharmaceutical industry. 3) a good market penetration thanks to wholesaling (that includes a variety of complementary products at affordable prices imported directly from reliable GMP-manufacturers) and its own profitable retail outlets (i.e. pharmacies) and 4) a healthy growth (including a high amount of orders on hand for 2009), sustainability and profitability.

Click here to read a recent interview by Mr. Abt in Interview Blog.


Comments are closed.